ClinicalTrials.gg

Program

ALN-PNP

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver, led by Regeneron Pharmaceuticals.

Furthest: phase 2, since Dec 5, 20223 company-led studies, 2 open or runningNext primary completion: Aug 10, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals32 open or runningphase 2since Dec 5, 2022Dec 5, 2022Aug 10, 2027phase 2 · NCT05648214

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 5, 2022First study: phase 2 study in Fatty LiverFirst studyNCT05648214 · 172 planned · United States
  2. Aug 16, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT06024408 · 9 enrolled · South Korea
  3. Apr 7, 2026Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT07527910 · 204 planned · United States

Ahead

  1. Aug 10, 2027Primary completion: phase 2 study in Fatty LiverNCT05648214
  2. Mar 15, 2030Primary completion: phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT07527910

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07527910Non-alcoholic Fatty Liver Disease · United States2RecruitingMar 15, 2030204
NCT06024408Non-alcoholic Fatty Liver Disease · South Korea1CompletedJul 7, 20259
NCT05648214Fatty Liver · United States2RecruitingAug 10, 2027172

How it is read

Names in the registry

  • “ALN-PNP”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.